New drug aimed at stopping breast cancer return after surgery

NCT ID NCT06300411

First seen Feb 23, 2026 · Last updated May 01, 2026 · Updated 10 times

Summary

This early-phase trial tests a new drug called SRG-514, which is applied directly to the area where breast cancer is removed during surgery. The goal is to find the safest dose and see how the body handles it. About 24 adults with breast cancer who are having breast-conserving surgery will take part. The study focuses on safety and side effects, not yet on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Audie Murphy VA

    San Antonio, Texas, 78229, United States

  • Duke Cancer Center

    Durham, North Carolina, 27710, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo

    Rochester, Minnesota, 55905, United States

  • Memorial Health

    Savannah, Georgia, 31404, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.